Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ascelia Pharma ABOSTO:ACE -4.84%23 EV-to-OCF is -0.60 as of Aug. 11, 2026. GuruFocus rates OSTO:ACE with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 1,406 Biotechnology companies, Ascelia Pharma AB ranks worse than 66.5% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Ascelia Pharma AB's Enterprise Value is kr42.92 Mil.
Ascelia Pharma AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was kr-71.20 Mil. Therefore, Ascelia Pharma AB's EV-to-OCF for today is -0.60.
The historical rank and industry rank for Ascelia Pharma AB's EV-to-OCF or its related term are showing as below:
OSTO:ACE'
s EV-to-OCF Range Over the Past 10 Years
Min: -0.66 Med: 0 Max: -0.66
Current: -0.66
During the past 9 years, the highest EV-to-OCF of Ascelia Pharma AB was -0.66. The lowest was -0.66. And the median was .
OSTO:ACE's EV-to-OCF is ranked worse than 66.5% of 1406
companies
in the Biotechnology industry
Industry Median: -3.515
vs OSTO:ACE: -0.66
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ascelia Pharma AB (OSTO:ACE) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ascelia Pharma AB's PE Ratio (TTM) for today is calculated as:
Ascelia Pharma AB's share price for today is kr0.57.
Ascelia Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.590.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Ascelia Pharma AB EV-to-OCF Related Terms
Ascelia Pharma AB EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Ascelia Pharma AB's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ACE vs VRTX, REGN, RVMD: EV-to-OCF Comparison
For the Biotechnology subindustry, Ascelia Pharma AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascelia Pharma AB EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascelia Pharma AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Ascelia Pharma AB's EV-to-OCF falls into.
Ascelia Pharma AB's current Enterprise Value is kr42.92 Mil.
Ascelia Pharma AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-71.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascelia Pharma AB (OSTO:ACE) has a EV-to-OCF of -0.60 as of Aug. 11, 2026. According to the industry distribution chart, Ascelia Pharma AB ranks #935 out of 1406 companies in the Biotechnology industry, placing it in the top 66.5%.
Is Ascelia Pharma AB's EV-to-OCF too high?
Ascelia Pharma AB's current EV-to-OCF is -0.60. Based on the distribution chart, Ascelia Pharma AB ranks #935 out of 1406 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ascelia Pharma AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Ascelia Pharma AB's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascelia Pharma AB ranks #935 out of 1406 companies for EV-to-OCF. This places Ascelia Pharma AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Ascelia Pharma AB's current EV-to-OCF is -0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascelia Pharma AB stock overvalued right now?
Ascelia Pharma AB (OSTO:ACE) has a current EV-to-OCF of -0.60. The current EV-to-OCF is -0.60. Ascelia Pharma AB's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Ascelia Pharma AB (OSTO:ACE), the current EV-to-OCF is -0.60 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.
23GF Score
Get the complete analysis for OSTO:ACE
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ACE has been successfully added to your 
